Design, synthesis, biological evaluation, and 3D-QSAR analysis of podophyllotoxin-dioxazole combination as tubulin targeting anticancer agents. 2017

Zi-Zhen Wang, and Wen-Xue Sun, and Xue Wang, and Ya-Han Zhang, and Han-Yue Qiu, and Jin-Liang Qi, and Yan-Jun Pang, and Gui-Hua Lu, and Xiao-Ming Wang, and Fu-Gen Yu, and Yong-Hua Yang
State Key Laboratory of Pharmaceutical Biotechnology, NJU-NJFU Joint Institute of Plant Molecular Biology, Nanjing University, Nanjing, China.

The advancement of cancer-fighting drugs has never been a simple linear process. Those drug design professionals begin to find inspiration from the nature after failing to find the ideal products by creative drug design and high-throughput screening. To obtain new molecules for inhibiting tubulin, podophyllotoxin was adopted as the leading compound and 1,3,4-oxadiazole was brought in to the C-4 site of podophyllotoxin in this research. A series of seventeen podophyllotoxin-derived esters have been achieved and then evaluated their antitumor activities against four different cancer cell lines: A549, MCF-7, HepG2, and HeLa. Among all the compounds, compound 7c showed the best antiproliferating properties with IC50  = 2.54 ± 0.82 μm against MCF-7 cancer cell line. It was obvious that the content of ROS grew significantly in MCF-7 in a way depending on the dosage. The time- and dose-dependent cell cycle assays revealed that compound 7c could apparently block cell cycle in the phase of G2/M along with the upregulation of cyclin A2 and CDK2 protein. According to further studies, confocal microscopy experiment has certified that compound 7c could restrain cancer from growing by blocking the polymerization of microtubule. Meanwhile, compound 7c could be ideally integrated with the colchicine site of tubulin. In future, it would be feasible to selectively design tubulin inhibitors with the help of 3D-QSAR. This means that it is hopeful to develop compound 7c as a potential agent against cancer due to its biological characteristics.

UI MeSH Term Description Entries
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D010069 Oxadiazoles Compounds containing five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom which exist in various regioisomeric forms. Oxadiazole
D011034 Podophyllotoxin A lignan (LIGNANS) found in PODOPHYLLIN resin from the roots of PODOPHYLLUM plants. It is a potent spindle poison, toxic if taken internally, and has been used as a cathartic. It is very irritating to skin and mucous membranes, has keratolytic actions, has been used to treat warts and keratoses, and may have antineoplastic properties, as do some of its congeners and derivatives. Epipodophyllotoxin,CPH86,Condyline,Condylox,Podocon-25,Podofilm,Podofilox,Podophyllotoxin, (5R-(5 alpha,5a alpha,8a alpha,9 alpha))-Isomer,Podophyllotoxin, (5R-(5 alpha,5a alpha,8a alpha,9 beta))-Isomer,Podophyllotoxin, (5R-(5 alpha,5a alpha,8a beta,9 alpha))-Isomer,Podophyllotoxin, (5R-(5 alpha,5a beta,8a alpha,9 beta))-Isomer,Wartec,Warticon
D002453 Cell Cycle The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE. Cell Division Cycle,Cell Cycles,Cell Division Cycles,Cycle, Cell,Cycle, Cell Division,Cycles, Cell,Cycles, Cell Division,Division Cycle, Cell,Division Cycles, Cell
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D014404 Tubulin A microtubule subunit protein found in large quantities in mammalian brain. It has also been isolated from SPERM FLAGELLUM; CILIA; and other sources. Structurally, the protein is a dimer with a molecular weight of approximately 120,000 and a sedimentation coefficient of 5.8S. It binds to COLCHICINE; VINCRISTINE; and VINBLASTINE. alpha-Tubulin,beta-Tubulin,delta-Tubulin,epsilon-Tubulin,gamma-Tubulin,alpha Tubulin,beta Tubulin,delta Tubulin,epsilon Tubulin,gamma Tubulin
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis

Related Publications

Zi-Zhen Wang, and Wen-Xue Sun, and Xue Wang, and Ya-Han Zhang, and Han-Yue Qiu, and Jin-Liang Qi, and Yan-Jun Pang, and Gui-Hua Lu, and Xiao-Ming Wang, and Fu-Gen Yu, and Yong-Hua Yang
December 2019, European journal of medicinal chemistry,
Zi-Zhen Wang, and Wen-Xue Sun, and Xue Wang, and Ya-Han Zhang, and Han-Yue Qiu, and Jin-Liang Qi, and Yan-Jun Pang, and Gui-Hua Lu, and Xiao-Ming Wang, and Fu-Gen Yu, and Yong-Hua Yang
January 2015, European journal of medicinal chemistry,
Zi-Zhen Wang, and Wen-Xue Sun, and Xue Wang, and Ya-Han Zhang, and Han-Yue Qiu, and Jin-Liang Qi, and Yan-Jun Pang, and Gui-Hua Lu, and Xiao-Ming Wang, and Fu-Gen Yu, and Yong-Hua Yang
April 2017, European journal of medicinal chemistry,
Zi-Zhen Wang, and Wen-Xue Sun, and Xue Wang, and Ya-Han Zhang, and Han-Yue Qiu, and Jin-Liang Qi, and Yan-Jun Pang, and Gui-Hua Lu, and Xiao-Ming Wang, and Fu-Gen Yu, and Yong-Hua Yang
January 2014, Current topics in medicinal chemistry,
Zi-Zhen Wang, and Wen-Xue Sun, and Xue Wang, and Ya-Han Zhang, and Han-Yue Qiu, and Jin-Liang Qi, and Yan-Jun Pang, and Gui-Hua Lu, and Xiao-Ming Wang, and Fu-Gen Yu, and Yong-Hua Yang
November 2018, Cells,
Zi-Zhen Wang, and Wen-Xue Sun, and Xue Wang, and Ya-Han Zhang, and Han-Yue Qiu, and Jin-Liang Qi, and Yan-Jun Pang, and Gui-Hua Lu, and Xiao-Ming Wang, and Fu-Gen Yu, and Yong-Hua Yang
September 2014, Journal of medicinal chemistry,
Zi-Zhen Wang, and Wen-Xue Sun, and Xue Wang, and Ya-Han Zhang, and Han-Yue Qiu, and Jin-Liang Qi, and Yan-Jun Pang, and Gui-Hua Lu, and Xiao-Ming Wang, and Fu-Gen Yu, and Yong-Hua Yang
January 2023, SAR and QSAR in environmental research,
Zi-Zhen Wang, and Wen-Xue Sun, and Xue Wang, and Ya-Han Zhang, and Han-Yue Qiu, and Jin-Liang Qi, and Yan-Jun Pang, and Gui-Hua Lu, and Xiao-Ming Wang, and Fu-Gen Yu, and Yong-Hua Yang
January 2023, Assay and drug development technologies,
Zi-Zhen Wang, and Wen-Xue Sun, and Xue Wang, and Ya-Han Zhang, and Han-Yue Qiu, and Jin-Liang Qi, and Yan-Jun Pang, and Gui-Hua Lu, and Xiao-Ming Wang, and Fu-Gen Yu, and Yong-Hua Yang
October 2014, Bioorganic & medicinal chemistry,
Zi-Zhen Wang, and Wen-Xue Sun, and Xue Wang, and Ya-Han Zhang, and Han-Yue Qiu, and Jin-Liang Qi, and Yan-Jun Pang, and Gui-Hua Lu, and Xiao-Ming Wang, and Fu-Gen Yu, and Yong-Hua Yang
March 2015, European journal of medicinal chemistry,
Copied contents to your clipboard!